Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Product ID

Click to order products descending

Display 30 Products per page

Relugolix
Read More
Relugolix (Myovant Sciences/Takeda) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly inhibits GnRH receptors, rapidly reducing the circulating gonadotropin’s luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and leading to the suppression of testosterone in men.
January 18, 2018
Find out more
Ipatasertib
Read More
Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt.
February 26, 2020
Find out more
Apalutamide
Read More
Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas).
January 18, 2018
Find out more
Darolutamide
Read More
Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens to ARs, blocking nuclear translocation of ARs and AR-mediated gene expression. The AR signaling pathway is the primary pathway that drives prostate cancer growth.
January 18, 2018
Find out more
Dexferrum
Read More
Dexferrum (iron dextran; Luitpold Pharmaceuticals) is an intravenous (IV) iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Feraheme
Read More
Feraheme (ferumoxytol; AMAG Pharmaceuticals) is an intravenous (IV) iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Injectafer
Read More
Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD). It is administered intravenously and is dissociated into iron and sucrose once in circulation.
January 11, 2018
Find out more
NeoRecormon
Read More
NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Dengvaxia
Read More
Dengvaxia (tetravalent live-attenuated chimeric vaccine; Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric live-attenuated vaccines (LAVs).
January 4, 2018
Find out more
Omecamtiv Mecarbil
Read More
Omecamtiv mecarbil is a novel cardiac myosin activator that increases contractility in heart muscle through selectively activating the enzyme myosin ATPase.
December 11, 2017
Find out more
Vericiguat
Read More
Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway.
December 11, 2017
Find out more
Ofatumumab
Read More
Ofatumumab (Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation (CD)20 on the B-cell membrane. Ofatumumab binds effectively to both the small and large extracellular loops on CD20 and releases very slowly over time.
November 24, 2017
Find out more
ALKS 8700
Read More
ALKS 8700 is an oral monomethyl fumarate molecule being developed for the treatment of relapsing multiple sclerosis.
November 24, 2017
Find out more
Ocrevus
Read More
Ocrevus is a second-generation cluster of differentiation (CD)20 antibody. Similar to Roche’s blockbuster cancer drug Rituxan (rituximab), Ocrevus specifically targets CD20+ B cells, thus depleting lymphocytes that produce the autoimmune response.
November 24, 2017
Find out more
Mavenclad
Read More
Mavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which are cells that seem to be major players in MS pathological mechanisms.
November 24, 2017
Find out more
Zepsyre
Read More
Zepsyre (lurbinectedin; PharmaMar/Chugai) is a novel synthetic agent derived from the marine-derived alkaloid trabectedin that inhibits the transcription process.
August 17, 2017
Find out more
Vosevi
Read More
Vosevi ([sofosbuvir + velpatasvir + voxilaprevir]) is Gilead’s third-generation, pan-genotypic, interferon-free regimen. The fixed-dose combination contains the hepatitis C virus nucleotide NS5B inhibitor sofosbuvir, a second-generation NS5A inhibitor (velpatasvir), and the company’s NS3 protease inhibitor (voxilaprevir).
November 6, 2017
Find out more
Nimenrix
Read More
Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals from the age of six weeks. It induces the production of bactericidal antibodies against capsular polysaccharides of N. meningitidis group A, C, W-135, and Y.
September 3, 2019
Find out more
Apleway
Read More
Apleway (tofogliflozin; Chugai) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.
November 7, 2017
Find out more
Lusefi
Read More
Lusefi (luseogliflozin; Taisho) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.
November 7, 2017
Find out more
Tenelia
Read More
Tenelia (teneligliptin; Mitsubishi Tanabe) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut.
November 7, 2017
Find out more
Zafatek
Read More
Zafatek (trelagliptin; Takeda) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.
November 7, 2017
Find out more
Ximency
Read More
Ximency (Bristol-Myers Squibb) is a twice-daily fixed-dose combination of daclatasvir, a first-generation NS5A inhibitor; asunaprevir, an NS3 protease inhibitor; and beclabuvir, a non-nucleoside NS5B inhibitor. The combination is approved in Japan for the treatment of genotype 1 (GT-1) chronic hepatitis C virus infection.
November 6, 2017
Find out more
Vyxeos
Read More
Vyxeos (cytarabine/daunorubicin; Jazz Pharmaceuticals) is a liposomal formulation of a 5:1 molar ratio of cytarabine and daunorubicin – chemotherapy drugs which are currently administered as two separate intravenous injections as part of the 7+3 regimen for the treatment of acute myeloid leukemia.Vyxeos (cytarabine/daunorubicin; Jazz Pharmaceuticals) is a liposomal formulation of a 5:1 molar ratio of cytarabine and daunorubicin – chemotherapy drugs which are currently administered as two separate intravenous injections as part of the 7+3 regimen for the treatment of acute myeloid leukemia.
July 6, 2017
Find out more
Tymlos
Read More
Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development.
March 9, 2018
Find out more
Trintellix
Read More
Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix.
March 29, 2019
Find out more
Seroquel/Seroquel XR
Read More
The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors.
March 29, 2019
Find out more
Rydapt
Read More
Rydapt is a multiple kinase inhibitor that interferes with cellular signal transduction pathways.
July 6, 2017
Find out more
Rapastinel
Read More
Rapastinel is a synthetic tetrapeptide, comprising of threonine–proline–proline–threonine, that acts as a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor.
March 29, 2019
Find out more
Quizartinib
Read More
Quizartinib (Daiichi Sankyo) is an oral multi-tyrosine kinase inhibitor of the platelet-derived growth factor receptor, KIT/c-KIT, and FMS-like tyrosine kinase 3 (FLT3) receptor.
July 6, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *